About TerrainDx

The reasoning layer for diagnostic medicine.

What's on this page What TerrainDx is The science Available on request

About TerrainDx

A shared map for you and your doctor.

TerrainDx restores something modern medicine has lost: a shared, transparent picture of what might be going on, before the visit starts.

The patient walks in prepared, not anxious. The clinician sees the full landscape, not a ranked list. Both look at the same map. The conversation that follows is grounded in evidence, organized by what to do next, and traceable from probability back to source.

TerrainDx is a product of PJAMA IP LLC, founded by Paul Foster, MD — a board-certified internist with 25 years of practice and 15 years as an internal medicine residency program director. The instrument is built around a peer-reviewed call to redesign the diagnostic process6 and a provisional patent portfolio prepared with Kim IP Law Group (Voorhees, NJ).

The science

Six innovations behind the map.

Most diagnostic AI gives you a ranked list. TerrainDx gives you a navigable map of clinical possibility — calibrated against what's known and what's missing, with the reasoning visible at every step.

Six innovations make that possible. What follows is a tour — enough to see why the system behaves the way it does. The full math, calibration data, and worked examples are in the technical white paper, available on request.

Innovation 01

The map: visual chunking, not a ranked list.

Working memory holds 5–7 named chunks reliably; ranked lists past that point look readable but aren't actually processed4. A complex case has 40–120 plausible diagnoses — far beyond what either patient or clinician can hold from a list.

1
2
3
4
5
6
7
8
9
10

TerrainDx organizes the diagnostic landscape into territories of ~7 related diagnoses, each named for what its members share clinically. The eye reads the map as a place; the mind navigates by chunks.

Diagnostic landscape rendered as named territories across action lanes
A live diagnostic landscape: territories grouped by clinical pattern, distributed across action lanes (Confirm, Key Questions, Monitor, Cleared). Color and position encode threat density and decision pressure. Each territory holds a chunk the working memory can hold; the full differential becomes a place, not a list.
Patent pending — Innovation 01
Innovation 02

Bayesian likelihood ratios for every probability.

Every probability on the map is a real Bayesian posterior — not LLM intuition. Each finding carries a calibrated likelihood ratio anchored to published evidence; the posterior is normalized across the full landscape and tier-anchored against population prevalence.

Alt-click any probability in the live tool and the chain unfolds: prior, every LR contribution, posterior, and the source each LR was anchored to. No black box, because there is no box.

History waterfall: a single diagnosis with the top three supporting findings, the top three refuting findings, and the cumulative effect on probability — prior to posterior
The reasoning behind a single diagnosis. Population prior at the top; each clinical finding contributes a calibrated likelihood ratio that shifts probability up (supporting) or down (refuting). The top three of each are surfaced, with the rest tucked underneath; the posterior is the cumulative result. Every contribution is inspectable — no black box, because there is no box.
Patent pending — Innovation 02
Innovation 03

Factor-X: estimating the unknown using ecology.

Every clinical case has a hidden dimension: the diagnoses that weren't generated. Most diagnostic AI ignores it. TerrainDx estimates it directly, using methods from ecology that estimate species richness from incomplete sampling5.

The intuition: imagine ten graduate students surveying a forest. The number of species they collectively find isn't the answer — the structure of how often each species was seen tells you how much they probably missed.

Case A — saturated

10 students return with 10 individuals across 3 species, well-distributed.

Estimated unknown: small.

Case B — sparse

10 students return with 30 individuals across 30 species — each seen exactly once.

Estimated unknown: roughly an order of magnitude larger.

The same principle applies clinically. TerrainDx runs the case through a panel of specialty-trained agents, then estimates from the structure of their output how many plausible diagnoses likely sit outside what was generated. The output, normalized as Factor-X, appears to the user as “the wider view” — an explicit acknowledgment of what's still unsampled.

Key insight callout: Without Factor-X, the system assigns 100% of probability to known diagnoses; the patient's real condition might not be on the list at all
Patent pending — Innovation 03
Innovation 04

The psychology of the unknown — different for each user.

Putting the unknown explicitly on the map matters — but it matters differently for the clinician and the patient.

For the clinician

An explicit estimate of what the system likely missed prevents premature closure. When Factor-X is high, it's a signal to broaden the differential or seek additional history. When it's low, it's reassurance that the landscape is approximately complete — the prompt to engage System 2 only when needed.

For the patient

Counterintuitively, an explicit unknown is reassuring. It places the “what if it's something nobody's thought of?” fear into a bounded probability rather than an unbounded dread. Honesty about what we don't know is more comforting than a confident-sounding list that hides the gap.

Patent pending — Innovation 04
Innovation 05

Capturing case urgency: Severity max, Steptime, and Clinical Threat Density.

Standard triage collapses risk into one dimension. Real clinical risk is two: how bad it could get and how fast. TerrainDx captures both and combines them into a metric that reflects actual decision pressure.

Variable Definition What it captures
Severity max Worst plausible functional outcome How bad this could be if it goes the wrong way (death, permanent harm, hospitalization, vs. self-limiting).
Steptime Days to next clinically meaningful step How quickly a decision must be made — minutes for a STEMI, weeks for chronic fatigue workup.
CTD Clinical Threat Density The composite that reflects actual decision pressure.

The map renders CTD visually: territory color shifts as the metric rises; elevated diagnoses flag for attention. A 10% chance of an emergency at minutes-to-step is a different decision than the same probability at months-to-step — flat triage scales miss the gradient; CTD captures it. The clinician sees decision pressure as a place on the map, not as another numerical alarm.

Patent pending — Innovation 05
Innovation 06

Diagnostic Leverage Index and case perturbation.

Two innovations close the loop on bedside utility.

Diagnostic Leverage Index (DLI)

For every potential next step — a question, a finding, a test — TerrainDx computes how much that step would shift the differential. High-DLI questions surface as “Key Questions”; low-DLI ones are de-prioritized regardless of how routine. As findings come in, the ranking updates in real time.

Case perturbation

Patient stories are imperfect. Conventional decision-support takes the case as given and breaks silently when the input is off. TerrainDx perturbs the input deliberately and re-runs the analysis to see how much the differential shifts. Diagnoses that survive are robust; diagnoses that vanish under small perturbations are fragile and get a “needs confirmation” treatment.

Experienced clinicians do this implicitly (“if she's wrong about the timing, this changes”). TerrainDx makes it a visible quantity attached to every diagnosis on the map.

Patent pending — Innovation 06

A more detailed technical white paper covering each of these innovations, with citations and worked examples, is available on request.

Bibliography

  1. Newman-Toker DE, Peterson SM, Badihian S, et al. Diagnostic Errors in the Emergency Department: A Systematic Review. Agency for Healthcare Research and Quality (AHRQ) Comparative Effectiveness Review, 2022; updated estimates in Newman-Toker et al., BMJ Quality & Safety 2023. ↑ back
  2. Gallup. Honesty & Ethics in Professions, annual survey 2020–2024 — physicians’ “very high / high” rating fell from 77% (2020) to 53% (2024). ↑ back
  3. Shrank WH, Rogstad TL, Parekh N. Waste in the US Health Care System: Estimated Costs and Potential for Savings. JAMA 2019; 322(15): 1501–1509 — ~$210B+ annually attributed to overtreatment, failure of care coordination, and failure of care delivery. ↑ back
  4. Miller GA. The magical number seven, plus or minus two: some limits on our capacity for processing information. Psychological Review 1956; 63(2): 81–97. ↑ back
  5. Chao A. Nonparametric estimation of the number of classes in a population. Scandinavian Journal of Statistics 1984; 11: 265–270 (the original Chao1 estimator); bias-corrected variants subsequently developed by Chao and colleagues for sparse-sampling regimes. ↑ back
  6. Foster PN, Klein JR. Defining excellence: next steps for practicing clinicians seeking to prevent diagnostic error. Journal of Community Hospital Internal Medicine Perspectives 2016; 6(4) — the peer-reviewed call to redesign the diagnostic process that TerrainDx implements.

For deeper conversations

What's available on request.

If you'd like a deeper read on any part of the above, the following are available to qualified investors, partners, clinical collaborators, and journalists:

  • Three-pager investor brief — the full structured document covering problem, opportunity, approach, defensibility, founder, and regulatory posture. PDF.
  • Market & competitive analysis — TAM/SAM, segment timing, positioning vs ranked-list AI, conversational AI, EHR-embedded CDS.
  • Technical white paper — the science section above in expanded form, with citations, formulas, worked examples, and validation data.
  • Defensibility & IP brief — provisional patent claim families, trademark filings, trade-secret architecture, and patent counsel of record (Kim IP Law Group, Voorhees, NJ).
  • Demonstration access — a live walkthrough of the patient and clinician interfaces, scoped to your area of interest.
Request materials

Full citations for references on this page are in the Bibliography under the Science section.

TerrainDx is an information tool designed to help patients and clinicians prepare for diagnostic conversations. It does not diagnose, treat, cure, or prevent any disease or condition. The patient interface operates under General Wellness exception; the clinician interface is structured for the FDA’s Clinical Decision Support exception (FD&C Act §520(o)(1)(E)).